Hong Kong Pharma Digital Technology (NASDAQ:HKPD) Issues Earnings Results

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) posted its quarterly earnings results on Friday. The company reported ($0.04) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $3.15 million for the quarter.

Hong Kong Pharma Digital Technology Trading Up 2.5%

Shares of HKPD traded up $0.01 during midday trading on Friday, hitting $0.42. 17,812 shares of the company traded hands, compared to its average volume of 369,446. The stock has a 50-day moving average of $0.42 and a 200-day moving average of $0.58. Hong Kong Pharma Digital Technology has a one year low of $0.31 and a one year high of $2.58.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Hong Kong Pharma Digital Technology in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. purchased a new position in Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned 0.39% of Hong Kong Pharma Digital Technology as of its most recent SEC filing.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.